AR056202A1 - 4 'MODIFIED NUCLEOSIDS AS ANTIVIRAL AGENTS - Google Patents
4 'MODIFIED NUCLEOSIDS AS ANTIVIRAL AGENTSInfo
- Publication number
- AR056202A1 AR056202A1 ARP060104218A ARP060104218A AR056202A1 AR 056202 A1 AR056202 A1 AR 056202A1 AR P060104218 A ARP060104218 A AR P060104218A AR P060104218 A ARP060104218 A AR P060104218A AR 056202 A1 AR056202 A1 AR 056202A1
- Authority
- AR
- Argentina
- Prior art keywords
- nhr4
- optionally substituted
- value
- unsubstituted
- nr4nh2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Abstract
Compuestos, métodos y composiciones para tratar un huésped infectado con virus de inmunodeficiencia humana y virus de hepatitis B, método que comprende administrar una cantidad efectiva de un 4'-C-substituido-b-D- y b-L-nucleosido o una sal o prodroga farmacéuticamente aceptable del mismo. Reivindicacion 1: Un compuesto caracterizado porque comprende un b-D- y b-L-nucleosido o una sal o prodroga farmacéuticamente aceptable del mismo, que tiene una estructura definida por la formula (1) o por la formula (2), donde X es hidrogeno, F, Cl, Br, I, NH2, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4, SH, SR4, S(O)bR4, OH, OR4, N3, CN, o CF3; Y es hidrogeno, F, Cl, Br, I, NH2, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4, SH, SR4, S(O)bR4, OH, OR4, N3, CN, CF3, hidroximetilo, metilo, etilo opcionalmente substituido o no substituido, vinilo opcionalmente substituido o no substituido, 2-bromovinilo opcionalmente substituido o no substituido, etinilo opcionalmente substituido o no substituido; R1 es F o N3; R2 es OH, OR4, OC(O)R4, OPvO3vMxR4yR5z, PvO3vMxR4yR5z, OCH2PvO3vMxR4yR5z, OP(O)(OQ)a(NHR4)b, SH, SR4, S(O)bR4, SC(O)R4, NH2, NHC(O)R4, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4; R3 es F, ciano, azido, etinilo, clorovinilo, fluorovinilo, alquilo C1-6, alquilo C1-6 substituido con uno a tres átomos de halogeno, alquenilo C1-6 o alquinilo C1-6 con la condicion que cuando R1 es N3, entonces R3 no es hidroximetilo; Z es O, S, CH2 o C=CH2; A es N, CH, o CF; y R4 y R5 son iguales o diferentes y son alquilo inferior, alquenilo inferior, acilo de 1-17 átomos de carbono, arilo, o aralquilo; M es al menos un miembro seleccionado del grupo formado por H+, Na+, y K+; v tiene un valor de 1, 2, o 3; x, y, y z son independientes entre sí y tienen un valor de 0, 1, 2, 3 o 4; y a tiene un valor de 0 o 1, b tiene un valor de 1 o 2, y Q es M o R4.Compounds, methods and compositions for treating a host infected with human immunodeficiency virus and hepatitis B virus, a method comprising administering an effective amount of a 4'-C-substituted-bD- and bL-nucleoside or a pharmaceutically acceptable salt or prodrug. of the same. Claim 1: A compound characterized in that it comprises a bD- and bL-nucleoside or a pharmaceutically acceptable salt or prodrug thereof, having a structure defined by formula (1) or by formula (2), wherein X is hydrogen, F , Cl, Br, I, NH2, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4, SH, SR4, S (O) bR4, OH, OR4, N3, CN, or CF3; Y is hydrogen, F, Cl, Br, I, NH2, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4, SH, SR4, S (O) bR4, OH, OR4, N3, CN, CF3, hydroxymethyl, methyl, optionally substituted or unsubstituted ethyl, optionally substituted or unsubstituted vinyl, optionally substituted or unsubstituted 2-bromovinyl, optionally substituted or unsubstituted ethynyl; R1 is F or N3; R2 is OH, OR4, OC (O) R4, OPvO3vMxR4yR5z, PvO3vMxR4yR5z, OCH2PvO3vMxR4yR5z, OP (O) (OQ) a (NHR4) b, SH, SR4, S (O) bR4, SC (O) R4, NH2 (O) R4, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4; R3 is F, cyano, azido, ethynyl, chlorovinyl, fluorovinyl, C1-6 alkyl, C1-6 alkyl substituted with one to three halogen atoms, C1-6 alkenyl or C1-6 alkynyl with the condition that when R1 is N3, then R3 is not hydroxymethyl; Z is O, S, CH2 or C = CH2; A is N, CH, or CF; and R4 and R5 are the same or different and are lower alkyl, lower alkenyl, acyl of 1-17 carbon atoms, aryl, or aralkyl; M is at least one member selected from the group consisting of H +, Na +, and K +; v has a value of 1, 2, or 3; x, y, and z are independent of each other and have a value of 0, 1, 2, 3 or 4; and a has a value of 0 or 1, b has a value of 1 or 2, and Q is M or R4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72038805P | 2005-09-26 | 2005-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056202A1 true AR056202A1 (en) | 2007-09-26 |
Family
ID=37900393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104218A AR056202A1 (en) | 2005-09-26 | 2006-09-27 | 4 'MODIFIED NUCLEOSIDS AS ANTIVIRAL AGENTS |
Country Status (17)
Country | Link |
---|---|
US (1) | US8569478B2 (en) |
EP (2) | EP3159351A3 (en) |
JP (1) | JP2009510075A (en) |
KR (1) | KR20080065272A (en) |
CN (2) | CN101310021A (en) |
AR (1) | AR056202A1 (en) |
AU (1) | AU2006294807B2 (en) |
BR (1) | BRPI0616738A2 (en) |
CA (2) | CA2904692A1 (en) |
EA (1) | EA200800932A1 (en) |
ES (1) | ES2617582T3 (en) |
IL (1) | IL190390A0 (en) |
NZ (3) | NZ597544A (en) |
PT (1) | PT1937825T (en) |
UY (1) | UY29868A1 (en) |
WO (1) | WO2007038507A2 (en) |
ZA (1) | ZA200802723B (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN1849142A (en) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2'-branched nucleosides and flaviviridae mutation |
EP2345661A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
CN100532388C (en) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2'-fluorine-4'-substituted-nucleosides analog, preparation method and uses thereof |
WO2009052050A1 (en) * | 2007-10-15 | 2009-04-23 | Pharmasset, Inc. | Dioxolane thymine phosphoramidates as anti-hiv agents |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
AR074897A1 (en) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | NUCLEOSID PHOSPHORAMIDATES |
SG172361A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside analogs |
AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
JP2013514350A (en) * | 2009-12-17 | 2013-04-25 | メディヴィル・アクチエボラーグ | Novel 3'-deoxy-3'-methylidene-β-L-nucleoside |
EP2752422B1 (en) | 2010-03-31 | 2017-08-16 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
TW201329096A (en) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
MD4589C1 (en) | 2011-09-16 | 2019-03-31 | Gilead Pharmasset Llc | Pharmaceutical composition comprising sofosbuvir and uses thereof for treating hepatitis C virus |
EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
NZ702744A (en) | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
JP2015523337A (en) | 2012-05-23 | 2015-08-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Sulfilimine and sulfoxide process for producing festinavir |
UY34824A (en) | 2012-05-25 | 2013-11-29 | Janssen R & D Ireland | NUCLEOSIDES OF URACILO SPYROOXETHANE |
US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
EA030189B8 (en) | 2012-10-08 | 2018-10-31 | Иденикс Фармасьютикалз Ллс | 2'-chloro nucleoside analogs for hcv infection |
US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
NZ625087A (en) | 2013-01-31 | 2017-05-26 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
WO2014172264A1 (en) | 2013-04-16 | 2014-10-23 | Bristol-Myers Squibb Company | Method for producing festinavir using 5-methyluridine as starting material |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
US20160130260A1 (en) | 2013-06-13 | 2016-05-12 | Bristol-Myers Squibb Company | Tert-butyl sulphoxide method for producing festinavir |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
SG11201602595TA (en) | 2013-10-11 | 2016-04-28 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
KR101718242B1 (en) * | 2015-11-25 | 2017-03-21 | 주식회사 타미온 | Novel compound having HIV inhibitory activity and use thereof |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Loop coil degron body for target protein degradation |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
CN111995649A (en) * | 2020-04-09 | 2020-11-27 | 瀚海新拓(杭州)生物医药有限公司 | Pteridinone nucleotide analogue and pharmaceutical composition, preparation method and medical application thereof |
CN113501853B (en) * | 2021-09-13 | 2021-12-07 | 南京颐媛生物医学研究院有限公司 | 4-thiouracil deoxynucleoside phosphate and its antiviral medicine use |
WO2023085242A1 (en) * | 2021-11-12 | 2023-05-19 | 国立大学法人北海道大学 | Antiviral agent |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
ZA867013B (en) | 1985-09-17 | 1988-04-27 | Wellcome Found | Therapeutic nucleosides |
EP0332626A1 (en) | 1986-11-21 | 1989-09-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions for treating viral infections in humans |
DE3739366A1 (en) * | 1987-04-10 | 1988-10-27 | Boehringer Mannheim Gmbh | DESAZA-PURIN-NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN NUCLEIC ACID SEQUENCING AND AS AN ANTIVIRAL AGENT |
AU2526188A (en) | 1987-09-22 | 1989-04-18 | Regents Of The University Of California, The | Liposomal nucleoside analogues for treating aids |
NZ228645A (en) | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
US5041449A (en) * | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
SE464168B (en) * | 1989-07-19 | 1991-03-18 | Bo Fredrik Oeberg | ANTIVIRAL COMPOSITION CONSISTING OF A 3'-FLUORO-2 ', 3'-DIDEOXYNUCLEOSIDE COMPOUND AND AND 2', 3'-DIDEOXYNUCLEOSIDE COMPOUND (EXAMPLE AZT) |
US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
AU7623991A (en) | 1990-05-17 | 1991-11-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
CA2083386C (en) | 1990-06-13 | 1999-02-16 | Arnold Glazier | Phosphorous prodrugs |
US5817799A (en) * | 1990-07-23 | 1998-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5543389A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5414078A (en) * | 1991-04-05 | 1995-05-09 | Emory University | Preparation of 3'-substituted-2',3'-dideoxynucleosides and 2'-deoxynucleosides from acyclic, achiral precursors |
CA2112803A1 (en) | 1991-07-12 | 1993-01-21 | Karl Y. Hostetler | Antiviral liponucleosides: treatment of hepatitis b |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
DE4207363A1 (en) * | 1992-03-04 | 1993-09-09 | Max Delbrueck Centrum | ANTIVIRAL NUCLEOSIDE ANALOGS, THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE |
WO1994026273A1 (en) | 1993-05-12 | 1994-11-24 | Hostetler Karl Y | Acyclovir derivatives for topical use |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
DE19632823C1 (en) * | 1996-08-14 | 1997-11-20 | Symbio Herborn Group Gmbh & Co | Complexes of (+)-S-adenosyl-methionine and 3'-azido-2',3'-di:deoxy nucleoside compounds |
FI107059B (en) * | 1998-07-01 | 2001-05-31 | Metso Paper Inc | Molding press portion of a paper machine and method for transferring a web from a former to a pressing portion |
DE60005501T2 (en) | 1999-05-12 | 2004-06-24 | Yamasa Corp., Choshi | 4'-C-ETHYNYL-PYRIMIDINE NUCLEOSIDES |
BR0210594A (en) * | 2001-06-22 | 2005-11-01 | Pharmasset Ltd | (beta) -d or (beta) -1,3-halonucleoside |
US7589078B2 (en) * | 2003-02-19 | 2009-09-15 | Yale University | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections |
EP2345661A1 (en) * | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
US20090318380A1 (en) * | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
-
2006
- 2006-09-26 EA EA200800932A patent/EA200800932A1/en unknown
- 2006-09-26 PT PT68251206T patent/PT1937825T/en unknown
- 2006-09-26 EP EP16201801.4A patent/EP3159351A3/en not_active Withdrawn
- 2006-09-26 CN CNA2006800423211A patent/CN101310021A/en active Pending
- 2006-09-26 AU AU2006294807A patent/AU2006294807B2/en not_active Ceased
- 2006-09-26 CA CA2904692A patent/CA2904692A1/en not_active Abandoned
- 2006-09-26 NZ NZ597544A patent/NZ597544A/en not_active IP Right Cessation
- 2006-09-26 WO PCT/US2006/037470 patent/WO2007038507A2/en active Application Filing
- 2006-09-26 KR KR1020087009645A patent/KR20080065272A/en active Search and Examination
- 2006-09-26 US US12/067,995 patent/US8569478B2/en active Active
- 2006-09-26 JP JP2008533517A patent/JP2009510075A/en active Pending
- 2006-09-26 NZ NZ609146A patent/NZ609146A/en not_active IP Right Cessation
- 2006-09-26 BR BRPI0616738-1A patent/BRPI0616738A2/en not_active Application Discontinuation
- 2006-09-26 CA CA2623522A patent/CA2623522C/en not_active Expired - Fee Related
- 2006-09-26 CN CN2012103530710A patent/CN102924549A/en active Pending
- 2006-09-26 ES ES06825120.6T patent/ES2617582T3/en active Active
- 2006-09-26 NZ NZ567272A patent/NZ567272A/en not_active IP Right Cessation
- 2006-09-26 EP EP06825120.6A patent/EP1937825B1/en active Active
- 2006-09-27 AR ARP060104218A patent/AR056202A1/en unknown
- 2006-10-17 UY UY29868A patent/UY29868A1/en not_active Application Discontinuation
-
2008
- 2008-03-24 IL IL190390A patent/IL190390A0/en unknown
- 2008-03-27 ZA ZA200802723A patent/ZA200802723B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL190390A0 (en) | 2008-11-03 |
BRPI0616738A2 (en) | 2011-06-28 |
ES2617582T3 (en) | 2017-06-19 |
EA200800932A1 (en) | 2008-10-30 |
EP1937825A2 (en) | 2008-07-02 |
EP3159351A3 (en) | 2017-05-17 |
NZ567272A (en) | 2012-02-24 |
EP1937825B1 (en) | 2016-12-21 |
CN101310021A (en) | 2008-11-19 |
US8569478B2 (en) | 2013-10-29 |
CA2623522A1 (en) | 2007-04-05 |
AU2006294807B2 (en) | 2013-01-17 |
EP1937825A4 (en) | 2010-06-23 |
CA2623522C (en) | 2015-12-08 |
EP3159351A2 (en) | 2017-04-26 |
CA2904692A1 (en) | 2007-04-05 |
CN102924549A (en) | 2013-02-13 |
US20110021454A1 (en) | 2011-01-27 |
KR20080065272A (en) | 2008-07-11 |
JP2009510075A (en) | 2009-03-12 |
WO2007038507A3 (en) | 2007-09-13 |
ZA200802723B (en) | 2009-03-25 |
WO2007038507A2 (en) | 2007-04-05 |
NZ609146A (en) | 2014-08-29 |
UY29868A1 (en) | 2007-04-30 |
AU2006294807A1 (en) | 2007-04-05 |
PT1937825T (en) | 2017-03-08 |
NZ597544A (en) | 2013-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056202A1 (en) | 4 'MODIFIED NUCLEOSIDS AS ANTIVIRAL AGENTS | |
RU2358979C2 (en) | Modified fluorinated nucleoside analogues | |
JP2015535261A5 (en) | ||
TW200740773A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
JP2009536660A5 (en) | ||
CL2011002859A1 (en) | Spironucleoside compounds, HCV virus inhibitors; pharmaceutical composition of said compounds; use of the compound to treat hepatitis c. | |
PE20130151A1 (en) | STEREOSELECTIVE SYNTHESIS OF ASSETS CONTAINING PHOSPHORUS | |
AR049385A1 (en) | SULFONILETIL PHOSPHORODIAMIDATES | |
ATE512954T1 (en) | N-PHENYLDIOXOHYDROPYRIMIDINES SUITABLE AS INHIBITORS OF HEPATITIS C VIRUS (HCV). | |
AR054475A1 (en) | PHENYLPHOSPHATES SUBSTITUTED AS MUTUAL PROPHARMACES OF STEROIDS AND (BETA) -AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCOCONSTRICTION | |
AR040474A1 (en) | THIOPHENOLGLYCOSIDE DERIVATIVES, PROCEDURES FOR THE PREPARATION OF THE SAME, MEDICINES CONTAINING THESE COMPOUNDS, AND THE USE OF THE SAME | |
AR063707A1 (en) | CERTAIN AMIDAS REPLACED, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. | |
RS51725B (en) | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | |
RU2651892C3 (en) | Nucleoside phosphoramidates as antiviral agents | |
PE20090611A1 (en) | PROCEDURE FOR SYNTHESIZING COMPOUNDS USEFUL TO TREAT HEPATITIS C | |
EA202090514A1 (en) | ANTI-VIRAL AGAINST HEPATITIS IN | |
EA200970375A1 (en) | CONNECTIONS AND METHODS OF TREATMENT OF HEPATITIS C VIRUS | |
JP2011520815A5 (en) | ||
ATE546460T1 (en) | HEPATITIS C VIRUS INHIBITORS | |
AR047992A1 (en) | DIAMINOPIRIMIDINS AS ANTAGONISTS OF P2X3 AND P2X2 / 3 | |
AR075396A1 (en) | DERIVATIVES OF KINAZOLINES AND PHARMACEUTICAL COMPOSITIONS | |
RU2010140627A (en) | Pyrrolidine derivatives | |
AR063942A1 (en) | HEPATITIS C VIRUS PROTEASA INHIBITING OXYMYL COMPOUNDS | |
PE20160120A1 (en) | DERIVATIVES OF NUCLEOSIDE 4'-FLUORO-2'-METHYL SUBSTITUTED | |
RU2008106754A (en) | AGENT PREVENTIVE OVULATION AGENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |